Treatment of multiple sclerosis with interferon β1b

被引:0
|
作者
Dhib-Jalbut, S
McFarland, HF
机构
[1] Univ Maryland Hosp, Dept Neurol, Baltimore, MD 21201 USA
[2] NINCDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
来源
BAILLIERES CLINICAL NEUROLOGY | 1997年 / 6卷 / 03期
关键词
interferon beta(1b); Betaseron; multiple sclerosis;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Interferon beta(1b) is now an established therapeutic option for relapsing remitting multiple sclerosis. More recently, it has also been shown to slow down disease progression in secondary progressive multiple sclerosis. Interferon beta(1b)'s clinical effect is reflected in MRI studies demonstrating a dramatic effect in reducing disease activity. The drug is generally well tolerated, but its efficacy can be compromised in some patients by the emergence of neutralizing antibodies. This chapter will focus on interferon beta(1b) (Betaseron) treatment for multiple sclerosis, its clinical and MRI effects, and its putative mechanism of action.
引用
收藏
页码:467 / 480
页数:14
相关论文
共 50 条
  • [21] Early benefit of interferon β-1b in neuropsychiatric abnormalities in multiple sclerosis
    Sirbu, CA
    Constantin, D
    Tirca, A
    Popa, N
    Ocneanu, A
    Munteanu, R
    Chirtes, A
    Nitulescu, R
    Cristea, E
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S229 - S230
  • [22] Apolipoprotein Alleles and the Response to Interferon-β-1b in Multiple Sclerosis
    Carmona, Olga
    Masuet, Cristina
    Alia, Pedro
    Moral, Ester
    Alonso-Magdalena, Lucia
    Casado, Virginia
    Martin-Ozaeta, Gisela
    Arbizu, Txomin
    EUROPEAN NEUROLOGY, 2011, 65 (03) : 132 - 137
  • [23] Comparison of interferon β-1a subcutaneous and interferon β-1b on medication adherence in patients with multiple sclerosis
    Joyeux, A.
    Meletiche, D.
    Kozma, C.
    Dickson, M.
    Bennett, R.
    JOURNAL OF NEUROLOGY, 2009, 256 : S162 - S163
  • [24] Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal
    Khabirov, F. A.
    Babicheva, N. N.
    Khaibullin, T. I.
    Averyanova, L. A.
    Granatov, E. V.
    Akhmedova, G. M.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (09) : 113 - 122
  • [25] Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-β-1b: A case report
    Sahraian M.A.
    Moghadasi A.N.
    Owji M.
    Maboudi M.
    Kosari F.
    McGee J.C.
    Minagar A.
    Journal of Medical Case Reports, 7 (1)
  • [26] Successful Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis with Interferon β-1b
    Schmidt, S.
    AKTUELLE NEUROLOGIE, 2012, 39 : S22 - S23
  • [27] Interferon-β1b in Multiple Sclerosis: Effect on Progression of Disability and Clinical Markers of Treatment Response
    Carmona, Olga
    Casado, Virginia
    Moral, Ester
    Alonso-Magdalena, Lucia
    Martinez-Yelamos, Antonio
    Martinez-Yelamos, Sergio
    Martin-Ozaeta, Gisela
    Arbizu, Txomin
    EUROPEAN NEUROLOGY, 2008, 60 (06) : 279 - 284
  • [29] Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report
    Haruomi Nishio
    Tatsuo Tsukamoto
    Takeshi Matsubara
    Yoichiro Okada
    Ryosuke Takahashi
    Motoko Yanagita
    CEN Case Reports, 2016, 5 (2) : 179 - 183
  • [30] Sustained clinical effectiveness of interferon-β-1b in multiple sclerosis patients
    Shimpi, AV
    Layton, B
    Bashir, K
    ANNALS OF NEUROLOGY, 2004, 56 : S58 - S58